NIAID-funded study could offset harsh effects of antibiotics.
Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation. In their study, patients who underwent the procedure were randomly assigned into two groups: one group received standard care and the other received auto-FMT. The researchers found that auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, thus restoring patients’ digestive, immune and other essential functions. With standard care, beneficial bacteria typically take many weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases, including Clostridium difficile.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, provided funding for part of the project. The study report appears in Science Translational Medicine.
“This important study suggests that clinical intervention using auto-FMT can safely reverse the disruptive effects of broad-spectrum antibiotic treatment,” says NIAID Director Anthony S. Fauci, M.D. “If validated in larger studies, this approach may prove to be a relatively simple way to quickly restore a person’s healthy microbiome following intensive antimicrobial therapy.”
Allogenic hematopoietic cell transplantation involves a donor — often but not exclusively a family member — who gives the recipient stem cells that re-establish bone marrow production of blood cells and immune function to combat cancer. Antibiotics are essential to prevent bacterial infections in stem cell recipients. However, antibiotics also destroy beneficial bacteria that enhance immune function and resistance to infection. The loss of beneficial bacteria increases the risk of certain life-threatening infectious diseases and graft-versus-host disease (GVHD).
The study involved cancer patients who provided their own fecal sample, which was frozen and stored prior to their cell transplantation procedure. Weeks later, when physicians confirmed that the transplanted cells were growing, they assessed the status of the patients’ beneficial gut bacteria. The first 25 patients who lacked known beneficial bacteria were enrolled into the study and randomly assigned to the different treatment groups: 14 received auto-FMT by enema and 11 received standard-of-care.
The patients who received auto-FMT consistently regained bacterial diversity, composition and function; recovery of beneficial bacteria in the 11 control patients was delayed.
The researchers are continuing to monitor the study patients to determine if auto-FMT improves patient outcomes, such as the incidence and severity of bacterial, viral and fungal infections and the incidence and severity of GVHD. Whether FMT from a healthy donor would be as beneficial as the patient’s own fecal sample at restoring beneficial bacteria remains to be studied.
Learn more: Fecal microbiota transplantation helps restore beneficial bacteria in cancer patients
The Latest on: Fecal microbiota transplantation
[google_news title=”” keyword=”fecal microbiota transplantation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fecal microbiota transplantation
- Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantationon March 27, 2024 at 7:38 am
The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene ...
- Listen to your gut: Research discusses using microbiota analysis for precision health careon March 26, 2024 at 7:51 am
The human body harbors approximately 30 trillion microbes, known collectively as the microbiota. These microorganisms influence various bodily functions, including digestion and metabolism to immune ...
- Researchers Conduct First Fecal Microbiota Transplant in Dolphinson March 25, 2024 at 9:50 am
Scientists have successfully carried out pioneering fecal microbiota transplantations on Navy bottlenose dolphins that showed signs of gastrointestinal disease.
- Alteration of the Intestinal Microbiomeon March 21, 2024 at 5:00 pm
Although the most common application for FMT has been in the setting of recurrent CDI, there is ongoing research to assess benefit in other gastrointestinal diseases. These include inflammatory ...
- FDA Tries to Close the Lid on Poop Transplant Companyon March 15, 2024 at 7:28 am
FDA sent the letter to Michael Harrop, founder of Human Microbes, saying that claims made on the company's website indicate that its products should be classified as drugs and biological products.
- Guideline now recommends fecal microbiota transplant for the majority of recurrent C. diff patientson February 21, 2024 at 1:10 am
diff) infection. "Using fecal microbiota transplant, we take stool from a healthy donor and transfer it to the colon of the person with recurrent C. diff, restoring balance to their gut microbiome ...
- Fecal microbiota transplants: Past, present and futureon February 9, 2024 at 11:30 am
Yet, the treatment never took off. Krishna Rao, M.D., M.S., the co-founder and director of the Fecal Microbiota Transplantation program at the University of Michigan, points to a couple of reasons ...
- Fecal Microbiota Transplantation News and Researchon December 17, 2023 at 4:00 pm
A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite ...
- Fecal Microbiota Transplants: From Gut Infections to Psychiatric Disorderson July 26, 2023 at 8:28 am
Fecal transplantation is an established procedure for controlling recurrent Clostridium difficile infection by replenishing healthy bacteria in the gut. Researchers explore novel applications of fecal ...
via Bing News